Oryzon Genomics S.A. (0RDB.L)
EUR 2.76
(-1.43%)
EUR 2.76
(-1.43%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 15.66 Million USD | -6.79% |
| 2022 | 16.8 Million USD | 39.13% |
| 2021 | 12.08 Million USD | 3.88% |
| 2020 | 11.63 Million USD | 0.89% |
| 2019 | 11.52 Million USD | 48.41% |
| 2018 | 7.76 Million USD | 49.97% |
| 2017 | 5.17 Million USD | -1.76% |
| 2016 | 5.27 Million USD | -32.43% |
| 2015 | 7.8 Million USD | -58.51% |
| 2014 | 18.8 Million USD | 478.53% |
| 2013 | 3.25 Million USD | -25.33% |
| 2012 | 4.35 Million USD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 4.39 Million USD | 0.0% |
| 2024 Q1 | - USD | 0.0% |
| 2023 Q2 | 8.16 Million USD | 0.0% |
| 2023 FY | - USD | -100.0% |
| 2023 Q1 | - USD | -100.0% |
| 2023 Q4 | - USD | 0.0% |
| 2023 Q3 | - USD | -100.0% |
| 2022 Q2 | 7.53 Million USD | 0.0% |
| 2022 Q1 | - USD | -100.0% |
| 2022 FY | 16.8 Million USD | 39.13% |
| 2022 Q4 | 16.8 Million USD | 0.0% |
| 2022 Q3 | - USD | -100.0% |
| 2021 Q3 | - USD | -100.0% |
| 2021 Q2 | 5.81 Million USD | 0.0% |
| 2021 FY | 12.08 Million USD | 3.88% |
| 2021 Q4 | 12.08 Million USD | 0.0% |
| 2021 Q1 | - USD | -100.0% |
| 2020 Q1 | 3.66 Million USD | 12.67% |
| 2020 FY | 11.63 Million USD | 0.89% |
| 2020 Q4 | 2.77 Million USD | 81.47% |
| 2020 Q3 | 1.52 Million USD | -26.03% |
| 2020 Q2 | 2.06 Million USD | -43.65% |
| 2019 FY | 11.52 Million USD | 48.41% |
| 2019 Q4 | 3.25 Million USD | 10.36% |
| 2019 Q2 | 2.71 Million USD | 33.03% |
| 2019 Q1 | 2.04 Million USD | -3.84% |
| 2019 Q3 | 2.94 Million USD | 8.37% |
| 2018 Q3 | 1.5 Million USD | -21.6% |
| 2018 Q4 | 2.12 Million USD | 41.25% |
| 2018 FY | 7.76 Million USD | 49.97% |
| 2018 Q2 | 1.91 Million USD | 7.87% |
| 2018 Q1 | 1.77 Million USD | 104.31% |
| 2017 Q2 | 1.46 Million USD | 21.63% |
| 2017 Q1 | 1.2 Million USD | -16.04% |
| 2017 Q4 | 870.56 Thousand USD | -20.9% |
| 2017 Q3 | 1.1 Million USD | -25.0% |
| 2017 FY | 5.17 Million USD | -1.76% |
| 2016 Q3 | 1.38 Million USD | 24.03% |
| 2016 FY | 5.27 Million USD | -32.43% |
| 2016 Q4 | 1.43 Million USD | 3.96% |
| 2016 Q2 | 1.11 Million USD | -11.47% |
| 2016 Q1 | 1.25 Million USD | -15.63% |
| 2015 Q4 | 1.49 Million USD | 6.06% |
| 2015 Q1 | 1.28 Million USD | 15.87% |
| 2015 Q2 | 3.47 Million USD | 171.32% |
| 2015 FY | 7.8 Million USD | -58.51% |
| 2015 Q3 | 1.4 Million USD | -59.56% |
| 2014 Q4 | 1.1 Million USD | -4.09% |
| 2014 Q2 | 6.85 Million USD | 0.0% |
| 2014 Q3 | 1.15 Million USD | -83.17% |
| 2014 FY | 18.8 Million USD | 478.53% |
| 2014 Q1 | 6.85 Million USD | 0.0% |
| 2013 FY | 3.25 Million USD | -25.33% |
| 2012 FY | 4.35 Million USD | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Boiron SA | 493.24 Million EUR | 96.824% |
| Laboratorios Farmaceuticos Rovi, S.A. | 829.5 Million EUR | 98.111% |
| Vetoquinol SA | 529.27 Million EUR | 97.04% |
| Valneva SE | 153.71 Million EUR | 89.807% |
| AB Science S.A. | 970 Thousand EUR | -1515.205% |
| Nanobiotix S.A. | 30.05 Million EUR | 47.876% |
| PHAXIAM Therapeutics S.A. | 1.32 Million EUR | -1081.56% |
| Vivoryon Therapeutics N.V. | -3.62 Million EUR | 532.804% |
| BioSenic S.A. | 543 Thousand EUR | -2785.357% |
| ABIVAX Société Anonyme | 4.62 Million EUR | -239.05% |
| Formycon AG | 77.69 Million EUR | 79.835% |